Chronic Kidney Disease Market Set to Reach $109.33 Billion by 2032, Driven by Rising Prevalence and Technological Advancements
The Chronic Kidney Disease (CKD) market is experiencing significant growth, with projections estimating a rise from USD 72.88 billion in 2024 to USD 109.33 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period .
This growth is propelled by an increasing global burden of CKD, advancements in early detection and management, and the development of novel therapies and treatments. Key players such as Amgen, AstraZeneca, and Bayer are actively investing in research and development of innovative drugs, including SGLT2 inhibitors, mineralocorticoid receptor antagonists, and erythropoiesis-stimulating agents, aiming to slow CKD progression and reduce associated risks.
Ask for Sample to Know US Tariff Impacts on Market @https://www.maximizemarketresearch.com/request-sample/187290/
United States: Growth and Consolidation
The United States remains a significant market for CKD treatments, with approximately 37 million people affected by the disease. Notably, nearly 786,000 individuals are living with end-stage renal disease (ESRD), with 71% on dialysis and 29% having undergone kidney transplants .
The U.S. market is witnessing consolidation through strategic mergers and acquisitions. For instance, Asahi Kasei, a Japanese conglomerate, made a $1.1 billion takeover bid for Swedish pharmaceutical company Calliditas Therapeutics, aiming to expand its healthcare business, specifically focusing on immunology and related diseases .
Asia Pacific: Opportunities and Trends
The Asia Pacific region is emerging as a lucrative market for CKD treatments, driven by a growing aging population and increasing prevalence of diabetes and hypertension. Countries like China, India, and Japan are witnessing a surge in CKD cases, prompting healthcare providers to adopt advanced diagnostic methods and treatment options .
In terms of market dynamics, Asahi Kasei's acquisition of Calliditas Therapeutics also reflects the region's strategic importance, as the deal aims to enhance Asahi Kasei's global presence and expand its sales and development capabilities in Asia .
Request a Sample of the US Tariff Impact Analysis Report: https://www.maximizemarketresearch.com/request-sample/187290/
Europe: Trends and Updation
Europe is witnessing significant advancements in CKD treatment protocols. The European Medicines Agency has permitted Novo Nordisk to update the label of its diabetes drug, Ozempic, to include the reduction of risk for kidney disease events. This decision follows a successful trial demonstrating that semaglutide, the active ingredient in Ozempic, can reduce the risk of progression of kidney disease .
Additionally, Fresenius Medical Care, the world's largest kidney dialysis company, is launching an advanced dialysis treatment in the U.S., which promises better survival rates, having been successful in Europe .
Middle East and Africa: Growth and Opportunity
The Middle East and Africa region is experiencing a growing demand for CKD treatments, attributed to increasing urbanization, lifestyle changes, and a rise in non-communicable diseases. Healthcare infrastructure development and government initiatives are further supporting market growth in this region .
Why Wait? Request Your Free Sample and Start Exploring Today :https://www.maximizemarketresearch.com/request-sample/187290/
Market Segmentation: In-Depth Analysis:
by Type of Treatment
Medication
ACE inhibitors
Angiotensin II receptor blockers (ARBs)
Diuretics
Others
Dialysis
Kidney Transplantation
Other Therapies
Medication, Dialysis, Kidney Transplantation, and Other Therapies are the segments of the market. In 2024, the Chronic Kidney Disease Market Share was dominated by the Medication category. The rising incidence of CKD, advances in technology, and the creation of novel treatment options are all responsible for this. Angiotensin II receptor blockers (ARBs), ACE inhibitors, diuretics, and others are further subdivided into this category. The drugs known as ACE Inhibitors are frequently used to treat hypertension and lower proteinuria, which slows the progression of chronic kidney disease.
by End User
Hospitals & Clinics
Ambulatory Surgery Centres (ASCs)
Dialysis Centres
Others
by Route of Administration
Oral
Intravenous
Subcutaneous
by Diagnostic Methods
Blood Tests
Urine Tests
Imaging Tests
Biopsy
Interested in market analysis? Don't miss the summary of the research report for valuable insights:https://www.maximizemarketresearch.com/market-report/chronic-kidney-disease-market/187290/
Learn about the top players driving innovation in the Market :
1. Amgen Inc.
2. ProKidney
3. Reata Pharmaceuticals, Inc
4. Abbott Laboratories
5. F. Hoffmann-La Roche Ltd
6. Fresenius Medical Care AG & Co. KGaA
7. Siemens Healthineers
8. Cincor Pharma
9. Allena Pharmaceuticals
10.DiaMedica Therapeutics Inc
11.Lexicon Pharmaceuticals
12.AbbVie Inc.
13.AstraZeneca plc
14.Bayer AG
15.Bristol-Myers Squibb Company
16.GlaxoSmithKline plc
17.Johnson & Johnson
18.Keryx Biopharmaceuticals, Inc.
19.Kissei Pharmaceutical Co., Ltd.
20.Merck & Co. Inc.
21.Novartis International AG
22.Pfizer Inc
23.Sanofi SA
24.Teva Pharmaceutical Industries Ltd.
25.Roche Holding AG
Get Market Research Latest Trends :
Global Granulocyte Macrophage Colony Stimulating Factor Market https://www.maximizemarketresearch.com/market-report/global-granulocyte-macrophage-colony-stimulating-factor-market/69429/
Global Ankle-Brachial Index Measurement Market https://www.maximizemarketresearch.com/market-report/global-ankle-brachial-index-measurement-market/84325/
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
[email protected]
+91 96071 95908, +91 9607365656
